Human polymorphonuclear neutrophils rapidly incorporated radiolabeled platelet-activating factor, 1-O-Ihexadecyl-9, 10-3H21-2-acetyl-sn-glycero-3-phosphocholine (I3HIPAF), and then metabolized it into its sn-2-fatty acyl derivative. 
Introduction
Platelet-activating factor (PAF)' is a sn-glycero-3-phosphocholine (GPC) derivative. At position 1, it is ether linked to a long chain HPLC, high performance liquid chromatography; LDH, lactate dehydrogenase; homocholine-PAF, rac-l-O-hexadecyl-2-acetyl-glycero-3-phosphohomocholine; lyso-PAF, deacetylated derivative of PAF; PMN, polymorphonuclear neutrophil; PAF, l-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; [ 'H]PAF, 1-O-hexadecyl-9,1O[-H2]-2-acetyl-sn-glycero-3-phosphocholine; PC, diacylglycerophosphocholine; TLC, thin-layer chromatography; triethyl-PAF, rac-1-0-hexadecyl-2-acetyl-glycero-3-phospho-N',N',N'-triethylethanolamine. fatty alcohol; at position 2, it is esterified to acetic acid (1) (2) (3) . Platelets, polymorphonuclear neutrophils (PMN), monocytes, macrophages, and endothelium produce PAF when stimulated (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . These cells can also inactivate the phospholipid, principally by deacetylating it and transferring a long chain fatty acid into the vacated 2-position (16) (17) (18) (19) (20) . PAF activates platelets (1, 3, 21) , PMN (22, 23) , macrophages (24) , and smooth muscle (25, 26) in vitro; it causes anaphylactoid reactions when infused intravenously (22, 27, 28) and induces the local accumulation ofleukocytes when injected subcutaneously (29) . PAF thus may be a natural mediator of inflammatory, allergic, thrombotic, and shock reactions. The mechanism by which PAF activates target cells is ofinterest. Based on the phospholipids striking biological potency, its stereospecificity, and its ability to desensitize target cells, we suggested that cellular receptors were involved in transducing bioactivity (30) (31) (32) . Subsequent studies have indeed demonstrated specific binding sites for PAF in or on platelets, PMN, and smooth muscle-containing tissues (33) (34) (35) (36) while other studies have identified compounds that competitively inhibit PAF binding and bioactions (37) (38) (39) . In this report, we examine PAF metabolism concurrently with binding, track the subcellular movement of PAF and its metabolites, and characterize the location of PAF receptors.
Methods
Reagents and buffers. The following were purchased from Sigma Chemical Co., St. Louis, MO: PIPES, type II bovine serum albumin (BSA), cytochalasin B, 2-mercaptoethanol, diisopropylfluorophosphate, phenylmethylsulfonylfluoride, type IV cytochrome c, and ATP. Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden); ['H]concanavalin A (50 Ci/mmol) (New England Nuclear, Boston, MA); diacylglycerophosphocholine (PC) (Serdary Research Labs., London, Ontario, Canada); BudgetSolve (Research Products International Corp., Mount Prospect, IL); GF/ C glass microfiber filters (Whatman, Ltd., Maidstone, England); ethyl ether and high performance liquid chromatography (HPLC) grade methanol and chloroform (Fisher Scientific, Fair Lawn, NJ); and 0.25 cm silica gel thin layer chromatography (TLC) plates (Analtech, Inc., Newark, DE) (plates were preheated at 180°C for 3 h before use) were purchased from the indicated vendors. Binding and degranulation assays were performed in a modified Hanks' balanced salt solution (1.4 mM calcium chloride, 0.7 mM magnesium chloride, pH 7.4) (30). Cells were disrupted in a relaxation buffer containing (mM): KCl (100), NaCI (3), ATP (1), MgCl2 (3.5), and PIPES (10) (pH 7.3) (40).
Preparation oflipids. Deacetylated PAF (lyso-PAF) and unlabeled PAF were prepared from beef heart plasmalogens (30).
[3H]PAF was prepared from synthetic l-O-hexadec-9,10-enyl-2-lyso-GPC (natural isomer) (41) by reduction with tritium gas and acetylation of product (sp act, 56 Ci/mmol) (42). rac-1-O-Hexadecyl-2-acetyl-glycero-3-phosphohomocholine (homocholine-PAF) and rac-l-O-hexadecyl-2-acetylglycero-3-phospho-N',N',N'-triethylethanolamine (triethyl-PAF) were synthesized by procedures to be reported elsewhere. Lipid structures and purity (>95%) were determined in several TLC systems and by susceptibility to degradation with phospholipases C and A2, elemental analyses, nuclear magnetic resonance, and mass spectrometry (the last two analyses were done only on unlabeled compounds). The lipids were stored at -700C in methanol/chloroform (2:1, vol/vol). Before use, they were freed of organic solvents under a stream of nitrogen and taken up in Hanks' buffer containing BSA (2.5 mg/ml).
Degranulation assay. Human leukocytes (1.3 million; >95% PMN) were suspended in 0.5 ml Hanks' buffer; incubated at 370C for 20 min; treated with cytochalasin B (2.5 Ag) for 2-4 min; challenged for 5 min; placed on ice; and centrifuged (400 g, X 4 min, 40C) to obtain supernatant fluid that was assayed for lysozyme, fl-glucuronidase, and lactate dehydrogenase (LDH) (30) . Results are reported as net enzyme release; i.e., the percentage oftotal cellular enzyme released by challenged cells minus that released by identically treated but unchallenged cells. In the various studies, no release ofcytosolic LDH was detected indicating that release ofgranule-bound enzymes (lysozyme and jB-glucuronidase) reflected degranulation rather than cell lysis.
PMNfractionation. 4 X 10' PMN were isolated from human blood, suspended in relaxation buffer (14 ml), nitrogen cavitated, and centrifged to remove nuclei and undisrupted cells. The postnuclear suspension was fractionated over Percoll discontinuous gradients (40, 43, 44) . Fractions (1.9 ml) from these gradients were removed with a peristaltic pump. In some studies, 4 X 108 PMN were incubated with 200 pM [3H]PAF in 7 ml of Hanks' buffer (250 Mg/ml BSA) at 370C for an indicated interval.
The incubation was stopped by adding 35 ml of Hanks' buffer (40C), centrifuged, washed once with 42 ml of Hanks' buffer (40C), rewashed with 42 ml of relaxation buffer, and resuspended in 7 ml of relaxative buffer. Suspensions were then nitrogen cavitated, centrifuged to remove undisrupted cells and nuclei, and fractionated. In these studies, >80% of the initially added radiolabel was located in cells following the last wash. For some studies, disrupted PMN were fractionated and fractions enriched with the marker enzyme for membranes, alkaline phosphatase, were pooled, diluted in a Percoll-enriched dilution buffer ( 13.2 Percoll; 0.3 ml water; 1.5 ml dilution buffer [40, 43] ), and centrifuged (140,000 g, X2 h, 40C) (43) . The supernatant fluid was removed and the pelleted membranes were gently resuspended in Hanks' buffer before storing at 40C.
Binding assay. I X 107 PMN, 200 Ml of a fraction from Percoll gradients (to which 4 mM calcium chloride was added to offset the presence of calcium chelators), or 50 Ml of isolated membranes was suspended with a final volume of0.9 ml Hanks' buffer in a I.5-ml conical polyethylene microcentrifuge tube (Brinkmann Instruments, Inc., Westbury, NY). Suspensions were then simultaneously exposed to [3H]PAF (50 Al in Hanks' buffer containing BSA) plus unlabeled PAF (50 ul in BSAHanks' buffer) or BSA-Hanks' buffer (50 Ml). Unless otherwise specified, all studies were performed at 40C in a final volume of I ml containing 250 Mg BSA, 1.4 mM Ca2+, and 0.7 mM Mg2e. Following incubation for indicated periods, suspensions were suctioned through premoistened GF/C filters. The microfuge tubes were washed five times with 1.5 ml of Hanks' buffer (40C) and each wash was suctioned through the same filter. Filters were air dried, placed in the bottom of 10-ml plastic vials, overlaid with I ml of methanol for 5 min, and mixed with 7 (33) (34) (35) . The low affinity binding sites were fit to a straight line by the method of least squares using data obtained at high ligand concentrations, i.e., 6 respective affinity constants and total receptor numbers for low affinity receptors. These latter two values were 150 and 2.9 nmol/liter for whole cells and 560 and 18.8 nmol/liter for membranes. At each low concentration of PAF (i.e., 0.02-2 nM), the estimated amount of PAF bound to the low affinity receptors was subtracted from total bound PAF to obtain the amount of PAF bound to high affinity receptors. Bound/free ratios were derived using this latter estimate for bound ligand. Our studies assumed that PAF bound to the low affinity receptor was in equilibrium with the high affinity receptor. The resulting data were fit to a straight line (correlation coefficients > 0.9) by the method of least squares.
[3H] Concanavalin A labeling. 4 X 10' PMN in 50 ml of Hanks' buffer (no Ca2l or Mg2') were incubated with 1 nM [3H]concanavalin A at 200C for 20 min, diluted further with 50 ml ofHanks' buffer (40C), chilled to 40C, washed with 50 ml of Hanks' buffer (40C) and then 50 ml ofrelaxation buffer (40C). Cells were suspended in 7 ml ofrelaxation buffer before cavitating and fractionating, as described above.
[3H]PAF metabolism. I X I07 PMN were incubated in a final volume of I ml with Hanks' buffer, 200 pM [3HJPAF (±10 nm PAF), and 250
Mg BSA. Following a specified interval, suspensions were centrifuged (16,000 g, X5 s). Pelleted cells were washed twice in Hanks' buffer (40C).
Cells and pooled supernatant fluids were then separately extracted with 1.6 ml of methanol:chloroform (1:1, vol/vol) and, after isolation of the chloroform layers, extracted X2 with 0.8 ml of chloroform. The procedure always recovered >95% ofradioactivity in the pooled chloroform layers. Material was spotted on TLC plates and developed with chloroform/methanol/acetic acid/water (50:25:8:4; vol/vol). Strips (0.5 cm) of silica gel were sequentially scraped from the plates, overlaid with I ml of methanol, mixed with 7 ml of Budget-Solve, and measured for radioactivity as described above. Figs. 5 and 7) . acyl-GPC peaked in these fractions but also was points. First, Fig. 7 (Fig. 8 ). (31) . Degranulation thus may reflect the rate of high affinity receptor occupancy, intracellular transducing events, and ligand metabolism (Fig. 3) . These factors would tend to reduce the ligand's biological potencies without influencing its efficacy in binding assays performed at 4°C. We therefore make no conclusions about the relative roles of the high and low affinity receptors in transducing degranulation. Rather, the data in Fig.  8 (16, 17) . We find that this metabolism is strictly temperature dependent: it does not occur at 4VC (Fig. 2) , whereas it proceeds quantitatively and with remarkable rapidity at 370C (Fig. 3) . In addition, excess PAF enhanced the conversion of [3H]PAF to acylated product (compare the upper and lower panels of Fig. 3 ). These results are relevant to interpretations of previous studies. For instance, working at 4VC, we found 1,100 high affinity PAF receptors per PMN; at 370C, Valone and Goetzl (35) found 5 X 106 receptors. This discrepancy may be due, in part, to ligand metabolism at the more physiological temperature. Likewise, studies quantitating whole cell PAF production (4-15) measure net ligand accumulation. Actual PAF production may be much greater than accumulation if, as seen in Fig. 3 , cells can metabolize >75% of PAF within minutes.
[3H]PAF metabolism appeared to take place within PMN membranes since intact ligand occurred only in membranecontaining subfractions and acylated metabolite initially accumulated in these same sites (Fig. 4) . The results, however, cannot exclude a possibility that some [3H]PAF is instantaneously metabolized elsewhere. In separate studies (49), we have found acetylhydrase, the enzyme deacetylating PAF, principally in cytosol, and acyl transferase, the transacylating enzyme, in PMN membranes. Ligand may be sequentially attacked by cytosolic and membrane-bound enzymes as it sits on the inner leaf of plasmalemma. In any case, following acylation, the radiolabeled product then appears to be shuttled to other membranes including specific granules and, to a lesser extent, azurophilic granules. The elevated radioactivity seen in cytosol (fractions 1-4 or 5 in the lower panels of Fig. 4 ) may reflect transcytosolic movement (perhaps mediated by PC-specific exchange proteins [50] ) or, alternatively, an accumulation of acylated product in endoplasmic reticulum, which contaminates cytosolic fractions (Fig. 7) . It is interesting to note that acylated PAF may be an important source of metabolizable arachidonic acid, as well as PAF (16, 17, 51, 52) . Granule-bound phospholipids, then, may be crucial for the production of bioactive lipids.
In conclusion, the studies reported here support a clearer view of the way in which cells handle PAF. The ligand first enters cell surface membranes to interact with specific, functionally relevant receptors that are themselves integral membrane components. Alternatively, the intramembranous ligand is progressively converted to acylated product and transferred to granule subfractions. These two distinct fates appear competitive: receptor binding may sequester ligand from cytosolic hydrolase and thereby keep it intact for as much as 60 min (Fig. 4) ; on the other hand, metabolism may decrease the availability of ligand for receptor binding and indirectly result in its removal to granular membranes.
